Curcumin

Research Papers and Clinical Trials

Recent research on curcumin has explored its therapeutic potential across several disease areas, with a particular focus on neurological conditions, cancer, and inflammatory disorders.

Neurological Applications

Multiple 2026 studies have investigated curcumin's neuroprotective properties. Research published in Materials Today Bio examined engineered exosomes containing curcumin in Alzheimer's disease-like mice, finding improvements in cognitive decline through enhanced microglia-related neuropathology. Another study in Brain, Behavior, & Immunity - Health demonstrated that curcumin could alleviate brain injury from gas explosions by promoting beneficial M2 microglia polarization through TLR4-mediated pathways. Additionally, a state-of-the-art review in International Review of Neurobiology discussed curcumin's role in activating Nrf2 neuroprotective pathways for Parkinson's disease treatment.

Cancer Research

Several studies have explored curcumin's anti-cancer properties using novel delivery systems. Research in Drug Delivery and Translational Research investigated engineered extracellular vesicles that co-deliver curcumin with TRAIL protein as a combination therapy against drug-resistant cancers. Another study in Materials Today Bio examined a nanoceria-curcumin platform that enhanced radiotherapy effectiveness in triple-negative breast cancer by modulating the tumor microenvironment and suppressing inflammatory pathways.

Other Medical Applications

Additional research has examined curcumin's effects in diabetes complications, with a study in iScience showing sex-specific benefits of curcumin-loaded nanoparticles combined with insulin for eye and heart complications in type 2 diabetes mice.

Clinical Trials

Several completed clinical trials have tested curcumin in various conditions. These include a Phase 2 trial (NCT03140657) examining nanocurcumin's effects on immune cell responses in ankylosing spondylitis patients, and a Phase 3 study (NCT06605911) assessing topical curcumin for oral lichen planus treatment. Other completed trials have investigated curcumin's bioavailability in glioblastoma patients (NCT01712542) and its use in non-alcoholic fatty liver disease (NCT02369536). A Phase 3 periodontitis trial (NCT03790605) has unknown completion status.

Important Note: Many of these studies are preclinical research conducted in laboratory models. The clinical evidence for curcumin's effectiveness in humans remains limited, and more robust clinical trials are needed to establish its therapeutic benefits and safety profile across different conditions.